指南与共识呼吸道感染慢阻肺

减少雾化治疗中呼吸道感染传播风险的专家指导

Guidance on Mitigating the Risk of Transmitting Respiratory Infections During Nebulization by the COPD Foundation Nebulizer Consortium.
指南 / 共识 · Chest · 2023-11-15

COPD基金会雾化器联盟(CNC)组织多学科专家,针对雾化治疗时可能产生逃逸气溶胶(含患者呼出的生物气溶胶和可能被污染的医疗器械气溶胶)的感染传播风险,制定了两套指导声明,分别适用于医疗机构和家庭环境,旨在安全使用雾化疗法并回答大流行或常见呼吸道病原体暴露期间的关键问题。

要点

  • 雾化治疗可能产生逃逸气溶胶,需关注其感染传播风险。
  • CNC发布医疗机构和家庭环境两套指导声明以降低风险。
  • 未来需研究不同雾化器在实际场景中的传播风险及缓解措施效果。

核心结论

  • 为降低雾化治疗中逃逸气溶胶导致的感染传播风险,应制定并采用缓解策略,尤其在高传播性病毒背景下。

研究设计与样本

  • COPD基金会雾化器联盟(CNC)于2020年成立,由患者倡导者、肺科医生、重症医生、呼吸治疗师、临床科学家和药师组成的国际多学科合作组织,通过文献和指南回顾制定专家指导。

主要发现

  • CNC成员回顾了雾化相关文献和指南,制定了两套指导声明:一套用于医疗机构,一套用于家庭环境。
  • 支持雾化治疗增加疾病传播风险的证据尚不确凿,指南不一致和意见分歧导致使用不确定性。

临床怎么用

  • 临床可参考CNC指导声明,在雾化治疗时采取缓解措施以减少逃逸气溶胶,平衡治疗获益与感染传播风险。

局限性

  • 未来需研究不同雾化器类型在实际患者护理中与逃逸气溶胶相关的疾病传播风险,并评估缓解策略的有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nebulizers are used commonly for inhaled drug delivery. Because they deliver medication through aerosol generation, clarification is needed on what constitutes safe aerosol delivery in infectious respiratory disease settings. The COVID-19 pandemic highlighted the importance of understanding the safety and potential risks of aerosol-generating procedures. However, evidence supporting the increased risk of disease transmission with nebulized treatments is inconclusive, and inconsistent guidelines and differing opinions have left uncertainty regarding their use. Many clinicians opt for alternative devices, but this practice could impact outcomes negatively, especially for patients who may not derive full treatment benefit from handheld inhalers. Therefore, it is prudent to develop strategies that can be used during nebulized treatment to minimize the emission of fugitive aerosols, these comprising bioaerosols exhaled by infected individuals and medical aerosols generated by the device that also may be contaminated. This is particularly relevant for patient care in the context of a highly transmissible virus. RESEARCH QUESTION: How can potential risks of infections during nebulization be mitigated? STUDY DESIGN AND METHODS: The COPD Foundation Nebulizer Consortium (CNC) was formed in 2020 to address uncertainties surrounding administration of nebulized medication. The CNC is an international, multidisciplinary collaboration of patient advocates, pulmonary physicians, critical care physicians, respiratory therapists, clinical scientists, and pharmacists from research centers, medical centers, professional societies, industry, and government agencies. The CNC developed this expert guidance to inform the safe use of nebulized therapies for patients and providers and to answer key questions surrounding medication delivery with nebulizers during pandemics or when exposure to common respiratory pathogens is anticipated. RESULTS: CNC members reviewed literature and guidelines regarding nebulization and developed two sets of guidance statements: one for the health care setting and one for the home environment. INTERPRETATION: Future studies need to explore the risk of disease transmission with fugitive aerosols associated with different nebulizer types in real patient care situations and to evaluate the effectiveness of mitigation strategies.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Biney, Ari, Barjaktarevic, et al. Guidance on Mitigating the Risk of Transmitting Respiratory Infections During Nebulization by the COPD Foundation Nebulizer Consortium. Chest. 2023. PMID: 37977263. doi:10.1016/j.chest.2023.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。